CDE Releases “Common Issues and Technical Requirements for Replicable Lentiviral Vector Testing”
Release Date:
2024-11-01 14:37
News Brief
On October 29, the Center for Drug Evaluation of the National Medical Products Administration released “Common Issues and Technical Requirements for Replicable Lentiviral Detection” The issuance of this technical requirement aims to enhance the standardization of corporate R&D and regulatory submissions, establish a scientifically sound and standardized review and approval system, and accelerate the high-quality development of domestic cell and gene therapy products.
The document content can be downloaded by clicking the PDF file.
Common Issues and Technical Requirements for Replicable Lentiviral Detection.pdf
Summary of Key Issues
1. Sample testing requirements:
2. RCL detection method:
This primarily includes the indicator cell co-culture method and the endpoint assay. The FDA recommends using the indicator cell co-culture method to culture and amplify RCL present in viral samples during the manufacturing process—such as supernatants and cells at the end of the virus production phase—and performing repeat testing at the end of the culture period as the standard RCL detection procedure.
1) Induced co-culture method
The supernatant from the viral vector production batch and the final producer cells are co-cultured with a permissive cell line (such as C8166 cells) for at least five passages to amplify any potential RCL. Following the amplification culture, the co-culture is centrifuged, and the collected supernatant is again co-cultured with C8166 cells as an indicator phase; samples from this indicator phase are then collected for RCL detection.
2) Endpoint Detection Method
Given that different endpoint detection methods have varying degrees of applicability, applicants are encouraged to employ at least two endpoint detection methods based on distinct principles for RCL assays. Commonly used endpoint detection methods include sequence-based assays (such as psi-gag and VSV-G), reverse transcriptase activity assays (PERT), and functional protein assays (such as p24 protein), in order to mutually validate the accuracy and reliability of the assay results.
3. What are the general considerations for selecting the positive control virus in the assay method?
It is recommended to select wild-type HIV, attenuated HIV, or recombinant replication-competent lentiviral vectors that meet the sensitivity requirements for RCL verification as positive control viruses, and to ensure the representativeness of these positive control viruses. Hycells is one of the few testing platforms on the market that uses authentic, virulent HIV.
Positive control viruses are critical for validating the sensitivity of assay methods; therefore, it is recommended that the submission dossier include detailed information on the source of the positive control virus, its manufacturing process, key functional components, and biological titer. In addition, attention should be paid to the stability of the positive control virus during storage with respect to its genetic characteristics, growth properties, and biological titer.
Introduction to the Hycells RCL Testing Platform
The vaccine and infectious disease drug R&D and evaluation technology platform jointly established by Hycells Biotechnology and Beike Pharmaceuticals is equipped with BSL-3 and ABSL-3 The laboratory’s biosafety level certification provides RCL Testing with an inherent platform advantage. This platform is suitable for handling viruses that pose a high risk to humans, animals, plants, or the environment and can cause severe, even fatal, diseases through direct contact or aerosol transmission, such as SARS, H7N9, and MERS.
Platform Overview:
1. Providing compliant, standardized, and end-to-end RCL testing services
2. Capable of conducting on-site inspections and dual IND submissions in China and the U.S., with extensive experience in IND filing.
3. HIV-1 authentic virus control, BSL-3 biosafety laboratory environment, quality control in accordance with GLP standards.
4. Four detection methods are available: P24, psi-gag, VSV-G, and Pert, to minimize false positives.
RCL testing procedure:
Leveraging market demand and its robust technological platform, Hycells has amassed extensive development expertise in methods such as ELISA for p24 protein quantification, PCR targeting the Psi-gag sequence region, VSV-G–based polymerase chain reaction, and PERT. Hycells offers high-quality, fast-turnaround analytical testing services to help you conduct quality research rigorously and efficiently, thereby jointly advancing the high-quality development of cell and gene therapy products in China.
National toll-free consultation hotline: 021-36696819 。
Chief Business Officer: Mr. Xie, 15201775322 。
Scan the code to contact
Related News
(II) Security Assurance Section | Safety First, Defense Prioritized
Compliance‑driven traceability establishes a clear “identity” for the product, but the real test lies in safety. While a multi‑donor pooling strategy ensures batch‑to‑batch consistency, it also inevitably elevates the risk of pathogen introduction. In the face of these associated risks and challenges, Heyousheng has never compromised on its manufacturing standards—relying on more precise design to deliver on its promise of enhanced safety.
This article will examine how He Yousheng proactively integrates the quality management system into the hospital setting, translating compliance requirements into concrete, actionable practices starting at the sample collection stage, thereby establishing a trust‑based chain that can withstand audit scrutiny.
In selecting hPL raw materials, Heyousheng consistently upholds the principle that “safety is determined at the source.” The samples used in production are rigorously collected in accordance with applicable standards and undergo stringent donor screening, effectively mitigating the risk of disease transmission at the very outset. Moreover, from informed consent forms and ethical approvals to clinical‑grade collection under the GCP framework, Heyousheng has established a fully traceable documentation chain, ensuring that every sample is accounted for and verifiable. In contrast to the industry’s longstanding reliance on the conventional model of using expired blood supplies from blood banks, this approach represents a structural, generational upgrade.
Recently, the research team led by Researcher Bian Yingjie at the Guangzhou National Laboratory, in collaboration with partners from Sun Yat-sen University, published a study titled “Iron overload in the tumor microenvironment induces CD8⁺ T cell ferroptosis and dysfunction” in the internationally renowned academic journal Nature Communications.
Hycells Recruitment | Never Stop Exploring, Never Stop Innovating
The company consistently upholds its core values of “people‑centricity, quality first, and innovation as the foundation,” remains driven by technological innovation, and sets new industry benchmarks for domestic innovation, thereby laying a solid foundation for the development and global advancement of China’s innovative pharmaceutical sector.
The HiXpan® NK Serum-Free Culture Kit, Version 3.0, is manufactured in strict compliance with GMP standards, and its production system fully adheres to relevant guidelines and regulations, including the “818 Requirements,” positioning it for pharmaceutical‑grade manufacturing and applications.
Contact Us
Phone: 021-36696819
Mobile phone:13061948224(Ms. Yu)
Email:monika@hys-bio.com
Wuxi Headquarters: 4th Floor, No. 15-1, Xianfeng Middle Road, Anzhen Subdistrict, Xishan District, Wuxi City
Shanghai Branch: Room 503, Building 2, No. 999 Jiangyue Road, Minhang District, Shanghai
Official Website
WeChat Official Account
Message Board